Disinvestment in healthcare: an overview of HTA agencies and organizations activities at European level

Abstract

BackgroundIn an era of a growing economic pressure for all health systems, the interest for “disinvestment” in healthcare increased. In this context, evidence based approaches such as Health Technology Assessment (HTA) are needed both to invest and to disinvest in health technologies. In order to investigate the extent of application of HTA in this field, methodological projects/frameworks, case studies, dissemination initiatives on disinvestment released by HTA agencies and organizations located in Europe were searched.MethodsIn July 2015, the websites of HTA agencies and organizations belonging to the European network for HTA (EUnetHTA) and the International Network of Agencies for HTA (INAHTA) were accessed and searched through the use of the term “disinvestment”. Retrieved deliverables were considered eligible if they reported methodological projects/frameworks, case studies and dissemination initiatives focused on disinvestment in healthcare.Results62 HTA agencies/organizations were accessed and eight methodological projects/frameworks, one case study and one dissemination initiative were found starting from 2007. With respect to methodological projects/frameworks, two were delivered in Austria, one in Italy, two in Spain and three in U.K. As for the case study and the dissemination initiative, both came from U.K. The majority of deliverables were aimed at making an overview of existing disinvestment approaches and at identifying challenges in their introduction.ConclusionsToday, in a healthcare context characterized by resource scarcity and increasing service demand, “disinvestment” from low-value services and reinvestment in high-value ones is a key strategy that may be supported by HTA. The lack of evaluation of technologies in use, in particular at the end of their lifecycle, may be due to the scant availability of frameworks and guidelines for identification and assessment of obsolete technologies that was shown by our work. Although several projects were carried out in different countries, most remain constrained to the field of research. Disinvestment is a relatively new concept in HTA that could pose challenges also from a methodological point of view. To tackle these challenges, it is necessary to construct experiences at international level with the aim to develop new methodological approaches to produce and grow evidence on disinvestment policies and practices.Electronic supplementary materialThe online version of this article (10.1186/s12913-018-2941-0) contains supplementary material, which is available to authorized users.

A cost-effectiveness analysis of denosumab for the prevention of skeletal-related events in patients with multiple myeloma in four European countries: Austria, Belgium, Greece, and Italy

“…As modern healthcare systems have competing demands on HRU and spending 29 , it is increasingly important to demonstrate the value of novel treatments to multiple stakeholders 30 . Using clinical data from the 20090482 study 20 , an economic analysis conducted in the US concluded that denosumab was cost-effective vs ZA for SRE prevention in patients with MM from both a payer and societal perspective 31 .…”

Public perspectives on disinvestments in drug funding: results from a Canadian deliberative public engagement event on cancer drugs

“…Negative associations with disinvestment could be shared by members of the public, making it difficult to accept the fact that there is a need to disinvest from ‘low-value’ cancer drugs [22, 23]. This has prompted some HTA agencies to demand transparency in disinvestment practices and the frameworks that guide them, in particular to make explicit the need for public input in addition to other relevant stakeholders [24–26]. Public engagement regarding disinvestment decisions has been sought in the areas of assisted reproductive technologies, vitamin B 12 /folate pathology testing, beta interferons for multiple sclerosis, and decommissioning of older people’s care home services, among others [18, 20, 27–30].…”

What Influences the Outcome of Active Disinvestment Processes in Healthcare? A Qualitative Interview Study on five Recent Cases of Active Disinvestment

“…Furthermore, proposals for disinvestment (i.e. withdrawal, restriction, retraction or replacement [6,7]) of healthcare interventions and services have been made [5,8,9]. Reasons for disinvestment may be, among others, ineffectiveness, unsafety or a lack of value for money [10,11].…”